An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study of Metformin prolonged release tablets 1000 mg of Pinnacle Life Science Pvt. Ltd., in comparison with Glucophage®1000 mg XR tablets (Metformin Hydrochloride prolonged release tablets) of Merck Sante S.A.S in healthy, adult, human subjects under fasting conditions.
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study of Metformin prolonged release tablets 1000 mg of Pinnacle Life Science Pvt. Ltd., in comparison with Glucophage®1000 mg XR tablets (Metformin Hydrochloride prolonged release tablets) of Merck Sante S.A.S in healthy, adult, human subjects under fed conditions.
A randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, oral bioequivalence study comparing Test Product, Fixed Dose Combination of Dapagliflozin 10mg + Sitagliptin 100mg tablets of Pinnacle Life Science Pvt. Ltd., India and Reference Products, FORXIGA® (Dapagliflozin) 10 mg tablets of Astra Zeneca Ltd., and Januvia (Sitagliptin) 100mg tablets of MSD Ltd., in healthy, adult, human male subjects under fasting conditions
100 项与 Pinnacle Life Science Pvt Ltd. 相关的临床结果
0 项与 Pinnacle Life Science Pvt Ltd. 相关的专利(医药)
100 项与 Pinnacle Life Science Pvt Ltd. 相关的药物交易
100 项与 Pinnacle Life Science Pvt Ltd. 相关的转化医学